Sugi Predict

Sugi Predict / Compounds / Ethylparaben

Ethylparaben

Ethylparaben

SCHEMBL321650

CCOC(=O)c1ccc(O)cc1.COC(=O)c1ccc(O)cc1

nearest known ligand 0.85

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 5/20 0.85
▸ CA2 P00918 5/20 0.85
▸ CA12 O43570 4/20 0.85
▸ CA7 P43166 4/20 0.85
▸ CA9 Q16790 4/20 0.85
▸ CA14 Q9ULX7 4/20 0.85
▸ ESR1 P03372 3/20 0.85
▸ ESR2 Q92731 1/20 0.85
▸ ALDH1A1 P00352 3/20 0.62
▸ TSHR P16473 2/20 0.62
▸ TDP1 Q9NUW8 2/20 0.62
▸ CHRM1 P11229 1/20 0.62
▸ SLC6A2 P23975 1/20 0.62
▸ KDR P35968 1/20 0.62
▸ LMNA P02545 3/20 0.59
▸ CYP1A2 P05177 2/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ MAOA P21397 1/20 0.59
▸ CYP2D6 P10635 1/20 0.59
▸ MAPK1 P28482 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4444431 0.92 CA1 (0.70) CA1CA2CA12CA7CA9
Ethylparaben SCHEMBL28368 0.92 CA12 (1.00) CA1CA2CA12CA7CA9
SCHEMBL10537396 0.92 CA1 (0.70) CA1CA2CA12CA7CA9
Ethylparaben SCHEMBL5311680 0.92 CA12 (1.00) CA1CA2CA12CA7CA9
Propylparaben SCHEMBL8511003 0.92 ESR1 (0.78) CA1CA2CA12CA7CA9
Ethylparaben SCHEMBL23497074 0.90 CA12 (0.96) CA1CA2CA12CA7CA9
Ethylparaben SCHEMBL475792 0.90 CA12 (0.96) CA1CA2CA12CA7CA9
Ethylparaben SCHEMBL31655760 0.90 CA12 (0.96) CA1CA2CA12CA7CA9
Ethylparaben SCHEMBL31347872 0.90 CA12 (0.96) CA1CA2CA12CA7CA9
Ethylparaben SCHEMBL476012 0.90 CA12 (0.96) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105168055-B Whitening patch-lightening cosmetic containing sweet osmanthus phenylethanoid glycosides and preparation method thereof 浙江大学 2018-02-06 — — CN claimed
CN-118922458-A Copolymer and contact lens treating liquid 日油株式会社 2024-11-08 — — CN disclosed
US-20240016762-A1 DUAL ANALGESIC/ANTI-INFLAMMATORY COMPOSITIONS COMPRISING CB2 RECEPTOR AGONISTS, COMBINATIONS, AND METHODS OF USE THEREOF Altus Formulation Inc. (CA) 2024-01-18 — — US disclosed
WO-2023154417-A1 MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF C4 THERAPEUTICS, INC. (US) 2023-08-17 — — WO disclosed
EP-4199916-A1 DUAL ANALGESIC/ANTI-INFLAMMATORY COMPOSITIONS COMPRISING CB2 RECEPTOR AGONISTS, COMBINATIONS, AND METHODS OF USE THEREOF Altus Formulation Inc. (CA) 2023-06-28 — — EP disclosed
US-20230190760-A1 ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS C4 THERAPEUTICS, INC. (US) 2023-06-22 — — US disclosed
EP-4192450-A1 ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS C4 Therapeutics, Inc. (US) 2023-06-14 — — EP disclosed
EP-3989974-A1 COMPOSITIONS AND METHODS OF TREATING OR PREVENTING OCULAR INFECTIONS WITH FILOCICLOVIR Microbiotix, Inc. (US) 2022-05-04 — — EP disclosed
WO-2022036455-A1 DUAL ANALGESIC/ANTI-INFLAMMATORY COMPOSITIONS COMPRISING CB2 RECEPTOR AGONISTS, COMBINATIONS, AND METHODS OF USE THEREOF Altus Formulation Inc. (CA) 2022-02-24 — — WO disclosed
WO-2020263904-A1 COMPOSITIONS AND METHODS OF TREATING OR PREVENTING OCULAR INFECTIONS WITH FILOCICLOVIR MICROBIOTIX, INC. (US) 2020-12-30 — — WO disclosed
CN-101123940-B preservative agent CLARIANT PRODUKTE DEUTSCHLAND 2012-05-23 — — CN disclosed
WO-2012004308-A1 STABLE AQUEOUS FORMULATIONS COMPRISING POORLY WATER SOLUBLE ACTIVE INGREDIENTS KRKA, D.D., NOVO MESTO (SI) 2012-01-12 — — WO disclosed
EP-1886568-B1 Synergistic microbicidal compositions comprising a N-alkyl-1,2-benzisothiazolin-3-one and an alkylparaben ROHM & HAAS (US) 2011-08-03 — — EP disclosed
CN-101365413-A Formulations of low oil content comprising diphenylmethane derivatives SYMRISE GMBH & CO KG (DE) 2009-02-11 — — CN disclosed
CN-101123940-A Preservative agent CLARIANT PRODUKTE DEUTSCHLAND (DE) 2008-02-13 — — CN disclosed
CN-101005834-A Eyewash liquid for dry eye therapy SENJU PHARMA CO (JP) 2007-07-25 — — CN disclosed
EP-1066009-B1 MOISTENED COSMETIC EYE TREATMENT PADS UNILEVER PLC (GB) 2003-08-06 — — EP disclosed
EP-1066009-A1 MOISTENED COSMETIC EYE TREATMENT PADS UNILEVER PLC (GB) 2001-01-10 — — EP disclosed
WO-1999048456-A1 MOISTENED COSMETIC EYE TREATMENT PADS UNILEVER PLC (GB) 1999-09-30 — — WO disclosed
CN-1110865-A Amino acid derivatives EISAI CO LTD (JP) 1995-10-25 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016762-A1 DUAL ANALGESIC/ANTI-INFLAMMATORY COMPOSITIONS COMPRISING CB2 RECEPTOR AGONISTS, COMBINATIONS, AND METHODS OF USE THEREOF CNR2, CNR1, OPRL1 CA1 814/4885CA2 375/4885CA12 1349/4885
US-20230190760-A1 ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS IKZF1, IKZF3, CRBN CA1 4018/4885CA2 4353/4885CA12 4227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.